BioNotebook: Post-Thanksgiving blues for Exelixis, Pozen; Burrill notes tripling of M&A deals in 2014
This article was originally published in Scrip
Executive Summary
Public companies often try to sneak their bad news into the evening hours following stock market closing time on the day before Thanksgiving – or on the eve of any major holiday, really – but Pozen and Exelixis waited until everyone came back to work from their turkey dinners and meals of endless leftovers to announce the loss of a major partner and a bad set of Phase III results.
You may also be interested in...
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).